Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ipratropium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.98 |
| ▸ | MEN1 | O00255 | 3/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 5/20 | 0.80 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ipratropium SCHEMBL3853 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854301 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL107906 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL30987857 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6854302 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3852 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3854 | 1.00 | CHRM2 (0.98) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL3299299 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL22077027 | 0.99 | CHRM2 (1.00) | CHRM2CHRM5CHRM1CHRM3CHRM4 | |
| Ipratropium SCHEMBL6553361 | 0.99 | CHRM2 (0.96) | CHRM2CHRM5CHRM1CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10105316-B2 | Inhalation compositions comprising muscarinic receptor antagonist | Arven llac Sanayi Ve Ticaret A.S. (TR) | 2018-10-23 | — | — | US | disclosed |
| US-20150174064-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS | Arven IIac Sanayi Ve Ticaret A.S. (TR) | 2015-06-25 | — | — | US | disclosed |
| US-20150165038-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND SORBITOL | ARVEN ILAC SANAYI VE TICARET A.S. (TR) | 2015-06-18 | — | — | US | disclosed |
| US-20150157567-A1 | INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10105316-B2 | Inhalation compositions comprising muscarinic receptor antagonist | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM5 3/4885 |
| US-20150157567-A1 | INHALATION COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM5 3/4885 |
| US-20150174064-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND GLUCOSE ANHYDROUS | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM5 3/4885 |
| US-20150165038-A1 | COMPOSITIONS COMPRISING MUSCARINIC RECEPTOR ANTAGONIST AND SORBITOL | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM5 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.